Skip to main content

Evotec to Screen Compounds for Genentech

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Evotec said today that it will screen small molecule compounds for drug developer Genentech under a new collaborative agreement.

Under the multi-year alliance, Evotec will use its disease knowledgebase and drug discovery platform to test small molecule candidates for the Roche subsidiary. The research will include assay development, high-throughput screening, structural biology, and medicinal chemistry services, Hamburg-based Evotec said.

Financial terms of the agreement were not released.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.